← Eichor
Study identifier: NCT06564428 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration

Condition: Ovarian Neoplasms  ·  Sponsor: Peking University Third Hospital

PhaseN/A
Planned participants1000
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The aim of this project is to establish a bidirectional multicenter cohort of hereditary ovarian cancer and to describe the clinicopathologic features of hereditary ovarian cancer patients in our country. The risk prediction model of ovarian cancer for Chinese was established by following-up analysis of clinical and pathological information, genetic test results and detailed family history, to predict the risk of cancer in first-degree relatives of carriers of pathogenic/suspected pathogenic mutations, and to guide the intervention management of high-risk population of cancer. The study will identify novel tumor-causing mutations/predisposing genes by gene sequencing in a special family with hereditary tumor.

This description comes directly from the study's public registry record.

Talk to the study team

Yuan Li, Doctor  ·  18610689868  ·  yuanli@bimu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University Third HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06564428